Publications by authors named "Meaghan Stirn"

Claim this Profile
H
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.
Anthony Conley, Christopher Larson, Bryan Oronsky, Meaghan Stirn, Scott Caroen

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Anthony P Conley, Christina L Roland, Alberto Bessudo, Brian R Gastman, Victoria M Villaflor, Meaghan Stirn

Cancer Gene Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data Management 101 for drug developers: A peek behind the curtain.
Bryan Oronsky, Erica Burbano, Meaghan Stirn, Joanne Brechlin, Nacer Abrouk

Clin Transl Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β: the apex predator of immune checkpoints.
Bryan Oronsky, Pedro Cabrales, Babak Alizadeh, Scott Caroen, Meaghan Stirn

Future Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patent and Marketing Exclusivities 101 for Drug Developers.
Bryan Oronsky, Scott Caroen, Franck Brinkhaus, Tony Reid, Meaghan Stirn

Recent Pat Biotechnol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Tony R Reid, Nacer Abrouk, Scott Caroen, Bryan Oronsky, Meaghan Stirn

Clin Colorectal Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient.
Santosh Kesari, Jeannie Williams, Erica Burbano, Meaghan Stirn, Scott Caroen

Case Rep Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Meaghan Stirn

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.
Xiaoning Guo, Xiaohui Wang, Sui Shen, Bryan Oronsky, Tony R Reid, Meaghan Stirn

Am J Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Tony Reid, Bryan Oronsky, Jan Scicinski, Curt L Scribner, Susan J Knox, Meaghan Stirn

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance.
Bryan Oronsky, Corey A Carter, Tony R Reid, Jan Scicinski, Arnold Oronsky, Meaghan Stirn

Neoplasia· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Going viral: a review of replication-selective oncolytic adenoviruses.
Christopher Larson, Bryan Oronsky, Jan Scicinski, Gary R Fanger, Meaghan Stirn

Oncotarget· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis